Turn Therapeutics Reports Increased Net Loss and Progress in Clinical Trials for GX-03

Turn Therapeutics Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded a net loss of $5.8 million for the quarter, compared to a loss of $1.2 million in the same period last year. For the six months ended June 30, 2026, the net loss increased to $6.8 million from $1.6 million in the prior year. The increase in losses is attributed to higher operating expenses, particularly in research and development, which rose to $584,498 from $71,937 year-over-year, reflecting the company's ongoing clinical trials for its lead product, GX-03.

Total operating expenses for the second quarter of 2026 were $1.6 million, up from $1.4 million in the same quarter of 2025. The increase was driven by a rise in research and development costs, which were necessary for advancing clinical studies. General and administrative expenses decreased slightly to $1.2 million from $1.3 million, primarily due to reduced professional fees associated with the company's direct listing on Nasdaq. The company’s accumulated deficit as of June 30, 2026, stood at approximately $29.2 million.

In terms of strategic developments, Turn Therapeutics has made notable progress with its clinical programs. The company is currently conducting a Phase 2 clinical trial for GX-03, a topical therapy for atopic dermatitis, and has expanded patient enrollment based on interim analysis results. Additionally, the company has entered into a licensing agreement with Medline Industries for one of its FDA-cleared medical devices, which is expected to enhance its market presence.

Operationally, Turn Therapeutics reported a cash position of $10.3 million as of June 30, 2026, a significant increase from $5.1 million at the end of 2025. This increase was primarily due to financing activities, including $6.7 million raised through a loan agreement with Avenue Capital. The company anticipates that its current cash reserves will be sufficient to fund operations and research and development expenses into the third quarter of 2027. However, management has expressed concerns regarding the company's ability to continue as a going concern, emphasizing the need for additional funding to support ongoing clinical trials and operational costs.

Looking ahead, Turn Therapeutics plans to continue its focus on advancing GX-03 through clinical trials while exploring additional funding avenues, including equity and debt financing. The company estimates that it will require approximately $60 to $65 million to complete its planned Phase 3 trials for both atopic dermatitis and onychomycosis. The outlook remains cautious, as the company acknowledges the inherent risks and uncertainties associated with drug development and the need for substantial capital to achieve its strategic objectives.